Objective To analyze the HbA1c results of double heterozygotes of hemoglobin(Hb) NewYork and β-thalassemia detected by five different HbA1c detection systems,and compare the early-warning abilities of erroneous glycosylated hemoglobin results for Hb NewYork and β-thalassemia heterozygotes.Methods Peripheral blood samples from 40 patients without hemoglobinopathies with different range of HbA1c levels were collected to evaluate the consistency of the detected results.Variant Ⅱ system was used as the reference system which successfully completed NGSP Level Ⅰ laboratory certification.Variant Ⅱ Turbo 2.0 (V Ⅱ-T),Capillary 2 Flex Piercing(2FP),Primus Ultra2 (Ultra2)and Roche Modular PPI(PPI) 800 were used as the comparative systems.The HbA1 c in 2 sera from the patients with compand heterozygotes of Hb NewYork was detected by the above systems.Hemoglobin electrophoresis was performed.Gentypes of á-and β-globin genes were analyzed by GAP-PCR,hybridization and dideoxy chain termination method.Results The HbA1c values in non-hemoglobinophthy samples obtained using V Ⅱ-T 2.0,Ultra2,C2FP and PPI systems were well correlated with that of VⅡ system.The hemoglobin genotypes of the two cases of compand heterozygotes were aa/aa,βIVS-2-654/βNewYork and aa/aa,β41-42/βNewYork,respectively.The proportions of HbA were all 0 while the proportions of Hb NewYork were 93.5％ and 94.0％ respectively.The HbA1c results of the two cases detected were 4.3％ (23 mmol/mol)and 4.5％ (26 mmol/mol)by V Ⅱ,4.5 ％ (26 mmol/mol) and 4.6％ (27 mmol/mol) by VⅡ-T 2.0,no values and no values by C2FP,4.1％ (21 mmol/mol) and 4.3 ％ (23 mmol/mol) by Ultra2 and 4.2％ (22 mmol/mol) and 4.8 ％ (29 mmol/mol) by PPI systems,respectively.All the systems did not send warning for abnormal signs in profiles and results.Conclusion The five systems presented different early-warning ability for the double heterozygotes of Hb NewYork and β-thalassemia.The compand heterozygotes should theoretically not contain HbA1 c,but the systems V Ⅱ,V Ⅱ-T,Ultra2 and PPI showed detectable results of HbA1 c indicating all the four systems were not able to provide with early-warning.C2FP system did not report HbA1c result so it exhibited early-warning ability for the double heterozygote.%目的 通过分析不同糖化血红蛋白检测系统检测Hb NewYork合并β地中海贫血(简称“地贫”,双重杂合子)标本的结果,观察不同系统对该双重杂合子的预警能力.方法收集40例HbA1c不同分布范围的无血红蛋白病的标本,以通过NGSPⅠ级检测实验室认证的VariantⅡ(VⅡ)糖化血红蛋白检测系统作为参考系统,VariantⅡTurbo2.0(VⅡ-T)、Capillary 2 FlexPiercing(C2 FP)、Primus Ultra2 (Ultra2)、Modular PPI 800 (PPI)系统为比对系统检测标本,以判断比对系统与参考系统结果的一致性.收集2例异常血红蛋白Hb NewYork合并β地贫血患者全血及血清标本,用5个糖化血红蛋白检测系统检测2例标本HbA1c.用毛细管电泳法对2例标本进行血红蛋白电泳分析,用GAP-PCR、原位杂交及双脱氧链终止法检测血红蛋白基因.结果对于无血红蛋白病患者全血标本,其他4个检测系统与VariantⅡ系统的一致性良好.2例患者的血红蛋白基因型分别为aa/aa,βIVS-2-654/βNewYork;aa/aa,β41-42/β NewYork;HbA含量均为0％,Hb NewYork含量分别为93.5％和94.0％;VⅡ的HbA1c检测结果分别为4.3％ (23 mmol/mol)和4.5％ (26 mmol/mol);VⅡ-T2.0的检测结果分别为4.5％ (26 mmol/mol)和4.6％ (27 mmol/mol);C2FP未检出HbA1c;Ultra2的结果分别为4.1％ (21 mmol/mol)和4.3％ (23 mmol/mol);PPI的检测结果为4.2％ (22 mmol/mol)和4.8％ (29 mmol/mol).检测系统无异常报警.结论5个检测系统对Hb NewYork双重杂舍子的检测预警能力不同,Hb NewYork双重杂合子标本理论上不合HbA1c,VⅡ、VⅡ-T、Ultra2、PPI检测系统报告了HbA1c结果,对该标本无预警能力,而C2FP系统未报告检测结果,对此标本有预警能力.
展开▼
